



Hikma Pharmaceuticals PLC – Results of Annual General Meeting

LONDON, 25 May 2006 – Hikma Pharmaceuticals PLC (“the Company”) advises that at its Annual General Meeting of shareholders, held at the London Underwriting Centre, that began at 11.00am today, 25 May 2006, resolutions 1 to 12 contained in the Notice of Annual General Meeting were passed as ordinary resolutions on a show of hands, resolutions 13 and 14 were passed as special resolutions on a show of hands, and resolution 15 was passed as an ordinary resolution by way of a poll. The results of the poll are set out below:

Resolution 15	For	Against
Waiver of Rule 9 of the City Code on Takeovers and Mergers	36,581,606	2,561,802

Copies of the resolutions dealing with special business passed at the Annual General Meeting have been submitted to the UK Listing Authority for publication through the Listing Authority’s Document and Viewing Facility.

The total number of proxies received for each resolution is set out below.

Resolutions	For	Against	Vote withheld
1 Receipt of accounts, together with reports of the Directors and auditors	92,636,850	2,327,413	311,000
2 Declaration of final dividend	95,275,263	-	-
3 Reappointment of Mr Samih Darwazah as a Director of the Company	91,748,810	3,240,853	285,600
4 Reappointment of Mr Mazen Darwazah as a Director of the Company	92,879,942	2,309,213	86,108
5 Reappointment of Mr Ali Al-Husry as a Director of the Company	95,257,063	18,200	-
6 Reappointment of Mr Michael Ashton as a Director of the Company	95,275,263	-	-
7 Reappointment of Mr Breffni Byrne as a Director of the Company	95,275,263	-	-
8 Reappointment of Sir David Rowe-Ham as a Director of the Company	95,275,263	-	-
9 Reappointment of Deloitte & Touche as auditors of the Company	95,037,639	90,528	147,096

10	Authorise the Directors to set the remuneration of the auditors	95,257,063	18,200	-
11	Approval of the Board report on remuneration	89,267,907	2,930,733	3,076,623
12	Authorise the Directors to allot relevant securities up to an aggregate nominal amount of £5,559,947	95,103,719	880	170,664
13	Empower the Directors to allot equity securities for cash on a non pre-emptive basis up to an aggregate nominal amount of £833,992	95,103,719	880	170,664
14	Cancellation of unissued unclassified shares	95,104,599	-	170,664
15	Waiver of Rule 9 of the City Code on Takeovers and Mergers	36,571,606	2,561,802	3,279,631

The number of 10p ordinary shares in issue on 25 May 2006 was 167,287,607.

Waiver of Rule 9 of the City Code on Takeovers and Mergers

In relation to Resolution 15, at today's date, the total number of ordinary shares held by the Concert Party, is 60,446,652, representing a combined shareholding of 36.133% of the issued share capital of the Company. If all of the options held by members of the Concert Party are exercised and the share capital of the Company is not otherwise increased, the number of ordinary shares held by the Concert Party will increase to 62,966,652, representing 37.081% of the enlarged issued share capital of the Company.

Declaration of final dividend

The final dividend of 0.89 cents per share will be paid on 30 May 2006 to shareholders on the register on 28 April 2006. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend is 1.8755 US dollars to one Pound Sterling, equal to 0.47 pence per share. Shareholders resident in Jordan have been given the opportunity to receive the dividend in Jordanian Dinar, at a rate of 0.708 Jordanian Dinar per US dollar.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Henry Knowles +44 20 7399 2670
Company Secretary

Susan Ringdal +44 20 7399 2670
Investor Relations Director

Brunswick Group

Jon Coles / Wendel Verbeek / Justine +44 20 7404 5959
McIlroy / Alex Tweed

About Hikma

Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: Generic, Branded and Injectable Pharmaceuticals. Hikma's operations are based principally in the United States, the Middle East and North Africa ("MENA") region and Europe. In 2005, the Group had revenue of \$262 million and profit attributable to shareholders of \$44 million. At 31 December 2005, the Group had over 1,800 employees. For news and other information, please visit www.hikma.com.